Rotate the site of injection to avoid irritation or sterile abscess formation with repeat administration. Intramuscular Depot injection (fluphenazine decanoate or . PACKAGE LEAFLET: INFORMATION FOR THE USER. Modecate® 25mg/ml Injection fluphenazine decanoate. Is this leaflet hard to see or read? Phone . ADMINISTRATION). Fluphenazine decanoate is not indicated for the management of severely agitated psychotic patients or psychoneurotic.

Author: Mik Fek
Country: Reunion
Language: English (Spanish)
Genre: Career
Published (Last): 25 September 2008
Pages: 158
PDF File Size: 5.3 Mb
ePub File Size: 5.30 Mb
ISBN: 316-2-51978-722-5
Downloads: 95262
Price: Free* [*Free Regsitration Required]
Uploader: Yoshicage

Modecate Injection 25mg/ml

Phenothiazines may have deleterious effects on neuronal recovery following acute brain injuries. Periodic evaluation for movement disorders is recommended e. Patients with clinically significant neutropenia should be closely monitored for insegt and infection, and appropriate medical intervention should be instituted if necessary. Decanoare is contraindicated for use in patients with known hypersensitivity to fluphenazine or other phenothiazine hypersensitivity. Syndrome of inappropriate anti-diuretic hormone secretion has also been observed.

Monitor for sedation and respiratory depression.

PDR Search

The effect of fluphenazine on the QT interval is likely to be potentiated by concurrent use of other drugs that also prolong the QT interval. Minor No specific drug interactions were identified with systemic agents and apraclonidine during clinical trials. As daily dosages increase, administer in 2 to 3 divided doses fouphenazine needed in order to control symptoms or side effects.

Those with known hypersensitivity to phenothiazines or who are predisposed to undue reactions should have therapy initiated with oral or immediate-release parenteral fluphenazine hydrochloride before receiving fluphenazine decanoate. Chlorpromazine may interfere with the metabolism of phenytoin and thus precipitate phenytoin toxicity.

Sudden, unexpected deaths have been reported pwckage some patients, appearing to result ijsert asphyxia or cardiac arrest. Monitor for signs and symptoms of neuroleptic malignant syndrome NMSrestlessness, and agitation.

Minor When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as fluphenazine. Moderate Additive effects may be seen when phenothiazines are used concomitantly with other drugs with antimuscarinic activity, such as carbinoxamine, a sedating H1-blocker.


Antipsychotics are subject to periodic review for effectiveness, necessity, and the potential for gradual dose reduction GDR or discontinuation. inaert

For example, chlorpromazine concentrations increase by up to 5-fold in the presence of propranolol. Patients previously maintained on depot fluphenazine: The GDR may be considered clinically contraindicated if the target symptoms returned or worsened after the most recent GDR attempt within the facility and the physician has documented justification for why attempting additional dose reductions at that time would likely impair the resident’s function or increase distressed behavior.

Monitor for additive effects, unusual moods or decanotae, and warn about the potential effects to driving and other activities.

Torsade de fulphenazine TdP and complete atrioventricular block have been reported. Ibutilide administration can cause QT prolongation and TdP; proarrhythmic events should be anticipated. Because no certain drug specificity was found for the observed outcomes, the authors concluded that underlying pathology or unidentified confounders could possibly explain gluphenazine findings. Phenothiazine antipsychotics, such as fluphenazine, stimulate the release of prolactin and may induce infertility in either men or women, or may induce other endocrine abnormalities.

Moderate Phenothiazines are CNS depressant drugs that may have cumulative effects when administered concurrently and they should be used cautiously with anxiolytic, sedative, and hypnotic type drugs, such as the benzodiazepines.

A fall risk assessment should be completed recurrently in at-risk patients on long-term antipsychotic therapy. Dosage reduction of either agent may be required. For full list of excipients, see section 6. Elderly patients may be more susceptible to the sedative and hypotensive effects. The manufacturer of ezogabine recommends caution during concurrent use of medications known to increase the QT interval, such as fluphenazine.

Initially, 1 to 2. Additionally, rare cases of TdP have been spontaneously reported during postmarketing surveillance in patients receiving levofloxacin. Hematologic effects including leukopenia, neutropenia, and agranulocytosis have been associated with antipsychotic use.


There is no known effective treatment for tardive dyskinesia: Moderate Phenothiazines can potentiate the CNS depressant action of other drugs such as opiate agonists.

Active ingredient fluphenazine decanoate. Hydrocodone; Potassium Guaiacolsulfonate; Pseudoephedrine: Major Phenothiazine absorption is reduced when coadministered with activated charcoal.

fluphenazine decanoate

In patients who do require chronic therapy, the smallest dose and the shortest duration producing a satisfactory clinical response should be sought. Consider a dose reduction of one or both drugs. Abnormal skin pigmentation and lens opacities have sometimes been seen following long-term administration of high doses of phenothiazines.

The syndrome is characterised by hyperthermia, together with some or all of the following: When the pharmacologic effects and an appropriate dosage are apparent, an equivalent dose of fluphenazine decanoate may be administered.

Antipsychotics are not FDA-approved for this indication and the labeling of all antipsychotics contains a boxed warning noting an increased risk of death in geriatric patients being treated for behavioral problems associated with dementia. Moderate Mitotane can cause sedation, lethargy, vertigo, and other CNS side effects. After the first fingolimod dose, overnight monitoring with continuous ECG in a medical facility is advised for patients taking QT prolonging drugs with a known risk of torsades de pointes TdP.

Theoretically, fluphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation such as ceritinib. Hypothermia appears to occur more frequently during initiation of antipsychotic therapy or after dose increases.

In addition, cabergoline, a dopamine agonist, can diminish the effectiveness of dopamine antagonists such as the phenothiazines.